Moexipril free base

Moexipril is an orally active inhibitor of angiotensin-converting enzyme (ACE), and becomes effective by being hydrolyzed to moexiprila…

For research use only. Not for human or veterinary use.

Target Angiotensin-converting Enzyme (ACE) Apoptosis

Research area Cardiovascular Disease Neurological Disease

Purity >98% Stock Inquire

Data Sheet SDS COA

Moexipril structure

CAS No.: 103775-10-6

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
10 mg	USD 450.00	BP-00023-10mg	In stock	Get quote
25 mg	USD 830.00	BP-00023-25mg	In stock	Get quote
50 mg	USD 1,330.00	BP-00023-50mg	In stock	Get quote
100 mg	USD 2,130.00	BP-00023-100mg	In stock	Get quote
250 mg	USD 3,400.00	BP-00023-250mg	In stock	Get quote
500 mg	Inquire	BP-00023-500mg	In stock	Inquire

Need another size or custom synthesis? Request a quote.

Description

Moexipril is an orally active inhibitor of angiotensin-converting enzyme (ACE), and becomes effective by being hydrolyzed to moexiprila (hydrochloride). Moexipril exhibits antihypertensive and neuroprotective effects-.

Biological activity

In Vitro Moexipril is devoid of anti-inflammatory properties and has no effect on platelet function. Moexipril hydrolyzes to Moexiprilat, and Moexiprilat inhibits ACE in guinea pig serum as well as on purified ACE from rabbit lung with IC50s of 2.6 nM and 4.9 nM, respectively. Moexipril (0.01 nM-0.1 mM) exhibits high potency against both ACE in rats plasma and purified ACE from rabbit lung, with IC50s of 1.75 nM and 2.1 nM, respectively. Moexipril (0-100 μM, 24 h) significantly reduced the percentage of damaged neurons in a dose-dependent manner. Moexipril (0-100 μM, 24 h) significantly attenuates Fe2+/3+-induced neurotoxicity. Moexipril dose not cause significant changes in the percentage of apoptotic neurons. In Vivo Moexipril can not cross the blood-brain barrier. Moexipril (3 mg/kg, 30 mg/kg and 10 mg/kg; p.o.; once daily; 5 days) exhibits a dose-dependent and antihypertensive effects in renal hypertensive rats, spontaneously hypertensive rats and perinephritic hypertensive dogs, respectively. Moexipril (0.3 mg/kg, i.p.) significantly reduces the infarct area on the mouse brain surface in NMRI mice. Moexipril (0.1 mg/kg, i.p.) significantly attenuates the cortical infarct volume in Long-Evans rats.

Identifiers

SMILES: C([C@@H](N[C@@H](CCC1=CC=CC=C1)C(OCC)=O)C)(=O)N2CC=3C(C[C@H]2C(O)=O)=CC(OC)=C(OC)C3
InChIKey: UWWDHYUMIORJTA-HSQYWUDLSA-N

Specifications

MW (average): 498.5681
Formula: C₂₇H₃₄N₂O₇
CAS No.: 103775-10-6
Physical state: Solid
Color: White to off-white
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Documents

References

[1]. Chrysant, S.G. and G.S. Chrysant, Pharmacological and clinical profile of moexipril: a concise review. J Clin Pharmacol, 2004. 44(8): p. 827-36.

[2]. Friehe H, et al. Pharmacological and toxicological studies of the new angiotensin converting enzyme inhibitor moexipril hydrochloride. Arzneimittelforschung. 1997 Feb. 47(2):132-44.

[3]. Edling O, et al. Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril. J Pharmacol Exp Ther. 1995 Nov;275(2):854-63.

[4]. Ravati A, et al. Enalapril and moexipril protect from free radical-induced neuronal damage in vitro and reduce ischemic brain injury in mice and rats. Eur J Pharmacol. 1999 May 28;373(1):21-33.

Same target

Search Angiotensin-converting Enzyme (ACE)

Same research area

Search Cardiovascular Disease